Back to search

Peptide record

TPDB09860

Buforin IIb Antibacterial Anticancer Antifungal Antiparasitic Cell-penetrating Peptides Hemolysis Toxicity standard

21 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB09860

Peptide_Name

Buforin IIb

Activity

Antibacterial Anticancer Antifungal Antiparasitic Cell-penetrating Peptides Hemolysis Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides

Database_Source

AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF pep-lab Antifungipept CAFPdb CPPsite3.0 HemoPI Hemolytic2 PD_Hemolysis

Sequence_Type

standard

Has_Modification No

Description A 21-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.

Sequence

RAGLQFPVGRLLRRLLRRLLR

FASTA

>TPDB09860|Antibacterial;Anticancer;Antifungal;Antiparasitic;Cell-penetrating Peptides;Hemolysis;Toxicity|length=21
RAGLQFPVGRLLRRLLRRLLR

Formula C115H207N43O23

Absent Amino Acids NDCEHIKMSTWY

Common Amino Acids RL

Mass 2560.18

PI 13.18

Basic Residues 7

Acidic Residues 0

Hydrophobic Residues 10

Net Charge +7

Boman Index 1.57

Hydrophobicity -0.095

Aliphatic Index 148.57

Half Life

Mammalian: 1 hour Yeast: 2 min E.coli: 2 min

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 1

number

Amino Acid Distribution

A: 1 R: 7 N: 0 D: 0 C: 0 E: 0 Q: 1 G: 2 H: 0 I: 0 L: 7 K: 0 M: 0 F: 1 P: 1 S: 0 T: 0 W: 0 Y: 0 V: 1

Length

Formula

C115H207N43O23

Mass

2560.18

13.18

Net Charge

Boman Index

1.57

Hydrophobicity

-0.095

C_terminal_Modification

Free

Chirality

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antibacterial

Origin

histone H2A

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=14.7 µg/ml

Detail Source Activity Anticancer

Activity Measurement 14.7 µg/mL

Target

Cancer Type Leukemia Cancer

Cell Line CCRF-CEM

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=11.3 µg/ml

Detail Source Activity Anticancer

Activity Measurement 11.3 µg/mL

Target

Cancer Type Leukemia Cancer

Cell Line HL-60

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=8.2 µg/ml

Detail Source Activity Anticancer

Activity Measurement 8.2 µg/mL

Target

Cancer Type Leukemia Cancer

Cell Line K-562

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=17 µg/ml

Detail Source Activity Anticancer

Activity Measurement 17 µg/mL

Target

Cancer Type Leukemia Cancer

Cell Line MOLT-4

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=10.5 µg/ml

Detail Source Activity Anticancer

Activity Measurement 10.5 µg/mL

Target

Cancer Type Leukemia Cancer

Cell Line RPMI-8226

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 6 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=20.2 µg/ml

Detail Source Activity Anticancer

Activity Measurement 20.2 µg/mL

Target

Cancer Type Leukemia Cancer

Cell Line SR

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 7 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=15.1 µg/ml

Detail Source Activity Anticancer

Activity Measurement 15.1 µg/mL

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 8 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=11.5 µg/ml

Detail Source Activity Anticancer

Activity Measurement 11.5 µg/mL

Target

Cancer Type Breast Cancer

Cell Line NCI/ADR-RES

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 9 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=11.3 µg/ml

Detail Source Activity Anticancer

Activity Measurement 11.3 µg/mL

Target

Cancer Type Breast Cancer

Cell Line MDA-MB-231

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 10 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=11.7 µg/ml

Detail Source Activity Anticancer

Activity Measurement 11.7 µg/mL

Target

Cancer Type Breast Cancer

Cell Line HS578T

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 11 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=11.3 µg/ml

Detail Source Activity Anticancer

Activity Measurement 11.3 µg/mL

Target

Cancer Type Breast Cancer

Cell Line MDA-MB-435

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 12 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=10.6 µg/ml

Detail Source Activity Anticancer

Activity Measurement 10.6 µg/mL

Target

Cancer Type Breast Cancer

Cell Line MDA-N

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 13 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=12.9 µg/ml

Detail Source Activity Anticancer

Activity Measurement 12.9 µg/mL

Target

Cancer Type Breast Cancer

Cell Line BT-549

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 14 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=23.9 µg/ml

Detail Source Activity Anticancer

Activity Measurement 23.9 µg/mL

Target

Cancer Type Breast Cancer

Cell Line T-47D

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 15 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=11.7 µg/ml

Detail Source Activity Anticancer

Activity Measurement 11.7 µg/mL

Target

Cancer Type Lung Cancer

Cell Line A-549

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 16 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=12.1 µg/ml

Detail Source Activity Anticancer

Activity Measurement 12.1 µg/mL

Target

Cancer Type Lung Cancer

Cell Line EKVX

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 17 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=12.6 µg/ml

Detail Source Activity Anticancer

Activity Measurement 12.6 µg/mL

Target

Cancer Type Lung Cancer

Cell Line HOP-62

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 18 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=7.2 µg/ml

Detail Source Activity Anticancer

Activity Measurement 7.2 µg/mL

Target

Cancer Type Lung Cancer

Cell Line HOP-92

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 19 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=13.3 µg/ml

Detail Source Activity Anticancer

Activity Measurement 13.3 µg/mL

Target

Cancer Type Lung Cancer

Cell Line NCI-H226

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 20 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=10.8 µg/ml

Detail Source Activity Anticancer

Activity Measurement 10.8 µg/mL

Target

Cancer Type Lung Cancer

Cell Line NCI-H23

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 21 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=10.7 µg/ml

Detail Source Activity Anticancer

Activity Measurement 10.7 µg/mL

Target

Cancer Type Lung Cancer

Cell Line NCI-H322M

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 22 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=12.1 µg/ml

Detail Source Activity Anticancer

Activity Measurement 12.1 µg/mL

Target

Cancer Type Lung Cancer

Cell Line NCI-H460

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 23 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=11.2 µg/ml

Detail Source Activity Anticancer

Activity Measurement 11.2 µg/mL

Target

Cancer Type Lung Cancer

Cell Line NCI-H522

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 24 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=12.4 µg/ml

Detail Source Activity Anticancer

Activity Measurement 12.4 µg/mL

Target

Cancer Type Brain Tumor

Cell Line SF-268

Tissue Affected Brain

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 25 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=12.9 µg/ml

Detail Source Activity Anticancer

Activity Measurement 12.9 µg/mL

Target

Cancer Type Brain Tumor

Cell Line SF-295

Tissue Affected Brain

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 26 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=9.5 µg/ml

Detail Source Activity Anticancer

Activity Measurement 9.5 µg/mL

Target

Cancer Type Brain Tumor

Cell Line SF-539

Tissue Affected Brain

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 27 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=13.8 µg/ml

Detail Source Activity Anticancer

Activity Measurement 13.8 µg/mL

Target

Cancer Type Brain Tumor

Cell Line SNB-19

Tissue Affected Brain

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 28 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=15.5 µg/ml

Detail Source Activity Anticancer

Activity Measurement 15.5 µg/mL

Target

Cancer Type Brain Tumor

Cell Line SNB-75

Tissue Affected Brain

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 29 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=10.6 µg/ml

Detail Source Activity Anticancer

Activity Measurement 10.6 µg/mL

Target

Cancer Type Brain Tumor

Cell Line U-251

Tissue Affected Brain

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 30 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=9.5 µg/ml

Detail Source Activity Anticancer

Activity Measurement 9.5 µg/mL

Target

Cancer Type Skin Cancer

Cell Line LOXIMVI

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 31 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=10.9 µg/ml

Detail Source Activity Anticancer

Activity Measurement 10.9 µg/mL

Target

Cancer Type Skin Cancer

Cell Line MALME-3M

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 32 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=15.1 µg/ml

Detail Source Activity Anticancer

Activity Measurement 15.1 µg/mL

Target

Cancer Type Skin Cancer

Cell Line M14

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 33 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=11.1 µg/ml

Detail Source Activity Anticancer

Activity Measurement 11.1 µg/mL

Target

Cancer Type Skin Cancer

Cell Line SK-MEL-2

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 34 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=8.9 µg/ml

Detail Source Activity Anticancer

Activity Measurement 8.9 µg/mL

Target

Cancer Type Skin Cancer

Cell Line SK-MEL-5

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 35 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=12.5 µg/ml

Detail Source Activity Anticancer

Activity Measurement 12.5 µg/mL

Target

Cancer Type Skin Cancer

Cell Line UACC-257

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 36 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=10.6 µg/ml

Detail Source Activity Anticancer

Activity Measurement 10.6 µg/mL

Target

Cancer Type Skin Cancer

Cell Line UACC-62

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 37 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=12.2 µg/ml

Detail Source Activity Anticancer

Activity Measurement 12.2 µg/mL

Target

Cancer Type Renal Cancer

Cell Line 786-0

Tissue Affected Renal

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 38 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=10 µg/ml

Detail Source Activity Anticancer

Activity Measurement 10 µg/mL

Target

Cancer Type Renal Cancer

Cell Line A-498

Tissue Affected Renal

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 39 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=12 µg/ml

Detail Source Activity Anticancer

Activity Measurement 12 µg/mL

Target

Cancer Type Renal Cancer

Cell Line ACHN

Tissue Affected Renal

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 40 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=14.1 µg/ml

Detail Source Activity Anticancer

Activity Measurement 14.1 µg/mL

Target

Cancer Type Renal Cancer

Cell Line CAKI-1

Tissue Affected Renal

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 41 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=11 µg/ml

Detail Source Activity Anticancer

Activity Measurement 11 µg/mL

Target

Cancer Type Renal Cancer

Cell Line RFX393

Tissue Affected Renal

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 42 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=11.4 µg/ml

Detail Source Activity Anticancer

Activity Measurement 11.4 µg/mL

Target

Cancer Type Renal Cancer

Cell Line SN-12C

Tissue Affected Renal

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 43 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=13.1 µg/ml

Detail Source Activity Anticancer

Activity Measurement 13.1 µg/mL

Target

Cancer Type Renal Cancer

Cell Line TK-10

Tissue Affected Renal

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 44 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=10.6 µg/ml

Detail Source Activity Anticancer

Activity Measurement 10.6 µg/mL

Target

Cancer Type Renal Cancer

Cell Line UO-31

Tissue Affected Renal

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 45 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=9 µg/ml

Detail Source Activity Anticancer

Activity Measurement 9 µg/mL

Target

Cancer Type Ovarian Cancer

Cell Line IGROV1

Tissue Affected Ovary

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 46 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=15.2 µg/ml

Detail Source Activity Anticancer

Activity Measurement 15.2 µg/mL

Target

Cancer Type Ovarian Cancer

Cell Line OVRCAR-3

Tissue Affected Ovary

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 47 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=17.6 µg/ml

Detail Source Activity Anticancer

Activity Measurement 17.6 µg/mL

Target

Cancer Type Ovarian Cancer

Cell Line OVRCAR-4

Tissue Affected Ovary

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 48 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=13.8 µg/ml

Detail Source Activity Anticancer

Activity Measurement 13.8 µg/mL

Target

Cancer Type Ovarian Cancer

Cell Line OVRCAR-5

Tissue Affected Ovary

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 49 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=13 µg/ml

Detail Source Activity Anticancer

Activity Measurement 13 µg/mL

Target

Cancer Type Ovarian Cancer

Cell Line OVRCAR-8

Tissue Affected Ovary

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 50 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=12.6 µg/ml

Detail Source Activity Anticancer

Activity Measurement 12.6 µg/mL

Target

Cancer Type Ovarian Cancer

Cell Line SK-OV-3

Tissue Affected Ovary

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 51 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=11.2 µg/ml

Detail Source Activity Anticancer

Activity Measurement 11.2 µg/mL

Target

Cancer Type Colon Cancer

Cell Line COLO-205

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 52 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=14.6 µg/ml

Detail Source Activity Anticancer

Activity Measurement 14.6 µg/mL

Target

Cancer Type Colon Cancer

Cell Line HCT-116

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 53 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=13.2 µg/ml

Detail Source Activity Anticancer

Activity Measurement 13.2 µg/mL

Target

Cancer Type Colon Cancer

Cell Line HCT-15

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 54 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=17.6 µg/ml

Detail Source Activity Anticancer

Activity Measurement 17.6 µg/mL

Target

Cancer Type Colon Cancer

Cell Line HT-29

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 55 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=12 µg/ml

Detail Source Activity Anticancer

Activity Measurement 12 µg/mL

Target

Cancer Type Colon Cancer

Cell Line KM12

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 56 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=12.7 µg/ml

Detail Source Activity Anticancer

Activity Measurement 12.7 µg/mL

Target

Cancer Type Colon Cancer

Cell Line SW-620

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 57 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=12 µg/ml

Detail Source Activity Anticancer

Activity Measurement 12 µg/mL

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 58 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=15.3 µg/ml

Detail Source Activity Anticancer

Activity Measurement 15.3 µg/mL

Target

Cancer Type Prostate Cancer

Cell Line DU-145

Tissue Affected Prostate

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2008

Evidence 59 Activity

Activity

Activity Endpoint 0% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 100 µg/mL

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

0% Hemolysis | 100 | µg/mL | target cell: Human erythrocytes

Target

Target Cell Human erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Mechanism of action and specificity of antimicrobial peptides designed based on buforin IIb | Peptides | 2012

Evidence 60 Activity

Activity

Activity Endpoint 34% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 200 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

34% Hemolysis | 200 | µM | target cell: Human erythrocytes

Target

Target Cell Human erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

A cancer specific cell-penetrating peptide, BR2, for the efficient delivery of an scFv into cancer cells. | PLoS One | 2013

Evidence 61 Hemolysis

Source & Reference

source HemoPI PD_Hemolysis

Database Source PD_Hemolysis